The properties of the different methods examined in this work are summarized in Table 5. Table 5 Summary of the properties of the different methods   Sanger sequencing Pyrosequencing TheraScreen DxS StripAssay HRM   CE mark no no www.selleckchem.com/products/emricasan-idn-6556-pf-03491390.html yes yes no CE mark Limit of detection* 25-30 %* 5-10 %* 1 % below 1 % 5-10 %* Limit of detection* LY2090314 solubility dmso Turnaround time 2-3 days 2 days 1/2 day 1 day 1/2 day Turnaround time Ease of interpretation easy easy easy medium difficult Ease of interpretation Technician time 6 hrs 4 hrs 2 hrs 5 hrs 2 hrs Technician time Amount of input DNA

1 reaction 1 reaction 8 reactions 1 reaction 1 reaction Amount of input DNA Detection of rare mutations Yes

– can detect any mutation located between the primers. Yes – can detect any mutation within the short sequencing fragments. learn more No – can only detect 7 specific mutations. No – can only detect 10 specific mutations. Yes – can detect some mutations located between the primers. Detection of rare mutations Reagent cost 20 € 40 € 120 € 60 € 4 € Reagent cost Special equipment required Sequencer 70 000 € Pyrosequencer 150 000 € Real time PCR cycler 30 000 € PCR cycler 7 500 € HRM Real time PCR cycler 75 000 € Special equipment required * from reference of Tsiatis26 and Ogino27. We agree with Tsiatis et al. [27] that for research purposes more than one genotyping platform is necessary to reveal double mutations and to provide complementary

data. In clinical settings, the most readily accessible NSCLC sample type is needle or brush biopsy, which is examined cytologically while resected, or biopsied tumors processed by formaldehyde fixation and paraffin embedding (FFPE). Proportion of FFPE samples from all samples usually reflects the best local practice and experience. Unfortunately, the FFPE process alters significantly the quality of DNA, and in many cases the DNA isolation from cytology smears yields higher Bupivacaine quality albeit lower quantity of DNA.Very low quantity of available DNA isolated from cytological preparations was a major limiting factor in our comparative study, which we tried to overcome using frozen tissue from biobank, since it provides both high quality and quantity of DNA. Moreover, due to recent biobanking initiatives [38], we are more frequently facing situations, where the tumor molecular diagnostics is performed from frozen tissues. Of the 11 FFPE samples genotyped using both the StripAssay and TheraScreen, 5 samples could not be typed by at least one method, 2 samples were wildtype by both methods, 3 samples were mutant by both methods, and one sample was p.Gly12Asp by TheraScreen and wildtype by StripAssay.